13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0000200406
Total reported value
$798.7M
$798.7M
20 檔
32.9%
According to the latest 13F quarterly dataset, Johnson & Johnson managed an equity portfolio of $798.7M at the end of Q2 2025, spanning 20 distinct U.S. exchange-listed positions.
In Q2 2025, Johnson & Johnson adopted a defensive or profit-taking posture, trimming 1 positions and completely liquidating 0 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 40.83% | -1.98% | — | |
| 2 | MGTX | MeiraGTx Holdings plc | Stock-Other | 13.14% | +2.41% | — | |
| 3 | RAPP | Rapport Therapeutics Inc | Stock-Other | 8.55% | +0.75% | — | |
| 4 | LEGN | Legend Biotech Corp-adr | Stock-Other | 8.44% | +0.69% | — | |
| 5 | NBTX | Nanobiotix SA - Adr | Stock-Other | 7.62% | -0.06% | — | |
| 6 | CVRX | Cvrx Inc | Stock-Other | 7.15% | -3.25% | — | |
| 7 | PRCT | Procept Biorobotics CORP | Stock-Other | 6.10% | -0.36% | — | |
| 8 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 2.43% | +0.10% | — | |
| 9 | XNCR | Xencor Inc | Stock-Other | 1.82% | +0.13% | — | |
| 10 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 1.19% | — | — | |
| 11 | FATE | Fate Therapeutics Inc | Stock-Other | 1.05% | +0.52% | — | |
| 12 | NMRA | Neumora Therapeutics Inc | Stock-Other | 0.42% | -0.16% | — | |
| 13 | ✓ | Rallybio CORP | Stock-Other | 0.36% | — | — | |
| 14 | VOR | Vor Biopharma Inc. | Stock-Other | 0.34% | — | — | |
| 15 | NNOX | Nano-X Imaging Ltd. | Stock-Other | 0.25% | -0.03% | EXIT | |
| 16 | LAB | Standard Biotools Inc | Stock-Other | 0.11% | -0.01% | — | |
| 17 | LYEL | Lyell Immunopharma, Inc. | Stock-Other | 0.11% | — | -95.00% | |
| 18 | TORCEUR | Adicet Bio Inc | Stock-Other | 0.07% | — | — | |
| 19 | ✓ | Biomx Inc | Stock-Other | 0.01% | — | — | |
| 20 | SENS1GBP | Senseonics Holdings Inc | Stock-Other | 0.01% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PTGX | Protagonist Therapeutics Inc | +6.2% | — | Unchanged |
| 2 | NBTX | Nanobiotix SA - Adr | +1.7% | — | Unchanged |
| 3 | RAPP | Rapport Therapeutics Inc | +1.2% | — | Unchanged |
| 4 | LEGN | Legend Biotech Corp-adr | +0.4% | — | Unchanged |
| 5 | FATE | Fate Therapeutics Inc | +0.3% | — | Unchanged |
| 6 | ARWR | Arrowhead Pharmaceuticals In | +0.3% | — | Unchanged |
| 7 | VOR | Vor Biopharma Inc. | +0.1% | — | Unchanged |
| 8 | NNOX | Nano-X Imaging Ltd. | 0% | — | Unchanged |
| 9 | LAB | Standard Biotools Inc | 0% | — | Unchanged |
| 10 | PRCT | Procept Biorobotics CORP | — | — | Unchanged |
| 11 | SENS1GBP | Senseonics Holdings Inc | — | — | Unchanged |
| 12 | TORCEUR | Adicet Bio Inc | 0% | — | Unchanged |
| 13 | ✓ | Biomx Inc | 0% | — | Unchanged |
| 14 | LYEL | Lyell Immunopharma, Inc. | 0% | -95.00% | Trim |
| 15 | MGTX | MeiraGTx Holdings plc | 0% | — | Unchanged |
| 16 | NMRA | Neumora Therapeutics Inc | -0.1% | — | Unchanged |
| 17 | ✓ | Rallybio CORP | -0.3% | — | Unchanged |
| 18 | XNCR | Xencor Inc | -0.5% | — | Unchanged |
| 19 | CTNM | Contineum Therapeutics Inc-a | -1.6% | — | Unchanged |
| 20 | CVRX | Cvrx Inc | -7.5% | — | Unchanged |
According to official SEC Form 13F filings, Johnson & Johnson reported a total U.S. public equity portfolio value of $798.7M across 20 disclosed positions in Q2 2025.
During Q2 2025, Johnson & Johnson's top holdings by market value included PTGX (40.8%)、MGTX (13.1%)、RAPP (8.6%). The largest single position, PTGX, represented 40.8% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including PTGX, MGTX, RAPP) accounted for 32.9% of total reported equity market value during Q2 2025.
Top Position Liquidated / Trimmed
LYEL
前期市值: $442.9K
In Q2 2025, Johnson & Johnson made 1 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 1 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.